Endothelial dysfunction is associated with activation of the type i interferon system and platelets in patients with systemic lupus erythematosus

RMD Open

Volumn 3, Issue 2, 2017, Pages

  Tydén, Helena ^a   Lood, Christian ^a   Gullstrand, Birgitta ^a   Nielsen, Christoffer Tandrup ^b,c   Heegaard, Niels H H ^b,d   Kahn, Robin ^a   Jönsen, Andreas ^a   Bengtsson, Anders A ^a  

^a LUND UNIVERSITY   (Sweden)

^b STATENS SERUM INSTITUT   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

cardiovascular disease; disease activity; inflammation; systemic lupus erythematosus

Indexed keywords

COMPLEMENT COMPONENT C4D; COMPLEMENT FACTOR; INTERFERON; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CARDIOVASCULAR PARAMETERS; CELL ASSAY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; REACTIVE HYPEREMIA INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; VERY ELDERLY;

EID: 85032581293     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2017-000508     Document Type: Article

References (47)

1. Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: The bimodal pattern revisited. Q J Med 1985;55:87-98.
2. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
3. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
4. Gustafsson JT, Svenungsson E. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity 2014;47:67-76.
5. Denny MF, Thacker S, Mehta H, et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: A potential pathway for premature atherosclerosis. Blood 2007;110:2907-15.
6. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-84.
7. Duffau P, Seneschal J, Nicco C, et al. Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med 2010;2:47-63.
8. May AE, Seizer P, Gawaz M. Platelets: Inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol 2008;28:s5-10.
9. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999;34:631-8.
10. Liao JK. Linking endothelial dysfunction with endothelial cell activation. J Clin Invest 2013;123:540-1.
11. Sergren A, Karp K, Boman K, et al. Atherosclerosis in early rheumatoid arthritis: Very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 2010;12:R158.
12. Tousoulis D, Antoniades C, Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart 2007;93:1001-7.
13. Parker B, Al-Husain A, Pemberton P, et al. Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus. Ann Rheum Dis 2014;73:1144-50.
14. Amabile N, Guin AP, Leroyer A, et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005;16:3381-8.
15. Esposito K, Ciotola M, Schisano B, et al. Endothelial microparticles correlate with endothelial dysfunction in obese women. J Clin Endocrinol Metab 2006;91:3676-9.
16. Hedblad B, Ogren M, Janzon L, et al. Low pulse-wave amplitude during reactive leg hyperaemia: An independent, early marker for ischaemic heart disease and death. Results from the 21-year followup of the prospective cohort study 'Men born in 1914', Malm Sweden. J Intern Med 1994;236:161-8.
17. Ogren M, Hedblad B, Isacsson SO, et al. Plethysmographic pulse wave amplitude and future leg arteriosclerosis. Atherosclerosis 1995;113:55-62.
18. Kuvin JT, Patel AR, Sliney KA, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J 2003;146:168-74.
19. Eloranta ML, Alm GV, Rnblom L. Disease mechanisms in rheumatology-tools and pathways: Plasmacytoid dendritic cells and their role in autoimmune rheumatic diseases. Arthritis Rheum 2013;65:853-63.
20. Thacker SG, Berthier CC, Mattinzoli D, et al. The detrimental effects of IFN-on vasculogenesis in lupus are mediated by repression of IL-1 pathways: Potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010;185:4457-69.
21. Kahlenberg JM, Kaplan MJ. The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus. Arthritis Res Ther 2011;13:203.
22. Lee PY, Li Y, Richards HB, et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007;56:3759-69.
23. Somers EC, Zhao W, Lewis EE, et al. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One 2012;7:e37000.
24. Lood C, Amisten S, Gullstrand B, et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: Up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 2010;116:1951-7.
25. Stellos K, Langer H, Daub K, et al. Platelet-derived stromal cellderived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation 2008;117:206-15.
26. Gladman DD, Ibaz D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
27. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
28. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
29. Bengtsson AA, Sturfelt G, Lood C, et al. Pharmacokinetics, tolerability, preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: Studies in lupus-prone mice and a multicenter, randomized, double-blind, placebocontrolled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:1579-88.
30. Leffler J, Martin M, Gullstrand B, et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol 2012;188:3522-31.
31. Nielsen CT, Lood C, Ostergaard O, et al. Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus. Lupus Sci Med 2014;1:e000026.
32. stergaard O, Nielsen CT, Iversen LV, et al. Quantitative proteome profiling of normal human circulating microparticles. J Proteome Res 2012;11:2154-63.
33. Nielsen CT, stergaard O, Johnsen C, et al. Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus. Arthritis Rheum 2011;63:3067-77.
34. Lood C, Eriksson S, Gullstrand B, et al. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus-a possible link to venous thrombosis Lupus 2012;21:1423-32.
35. Lood C, Tyd H, Gullstrand B, et al. Platelet activation and anti-phospholipid antibodies collaborate in the activation of the complement system on platelets in systemic lupus erythematosus. PLoS One 2014;9:e99386.
36. Bonetti PO, Barsness GW, Keelan PC, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 2003;41:1761-8.
37. Goor DA, Sheffy J, Schnall RP, et al. Peripheral arterial tonometry: A diagnostic method for detection of myocardial ischemia induced during mental stress tests: A pilot study. Clin Cardiol 2004;27:137-41.
38. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 2010;31:1142-8.
39. Peled N, Shitrit D, Fox BD, et al. Peripheral arterial stiffness and endothelial dysfunction in idiopathic and scleroderma associated pulmonary arterial hypertension. J Rheumatol 2009;36:970-5.
40. Rajagopalan S, Somers EC, Brook RD, et al. Endothelial cell apoptosis in systemic lupus erythematosus: A common pathway for abnormal vascular function and thrombosis propensity. Blood 2004;103:3677-83.
41. Chironi GN, Boulanger CM, Simon A, et al. Endothelial microparticles in diseases. Cell Tissue Res 2009;335:143-51.
42. Eschen O, Christensen JH, Dethlefsen C, et al. Cellular adhesion molecules in healthy subjects: Short term variations and relations to flow mediated dilation. Biomark Insights 2008;3:57-62.
43. Preston RA, Jy W, Jimenez JJ, et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 2003;41:211-7.
44. van Ierssel SH, Conraads VM, Van Craenenbroeck EM, et al. Endothelial dysfunction in acute brain injury and the development of cerebral ischemia. J Neurosci Res 2015;93:866-72.
45. Nhek S, Clancy R, Lee KA, et al. Activated Platelets Induce Endothelial Cell Activation via an Interleukin-1Pathway in Systemic Lupus Erythematosus. Arterioscler Thromb Vasc Biol 2017;37:707-16.
46. Robinson SD, Harding SA, Cummins P, et al. Functional interplay between platelet activation and endothelial dysfunction in patients with coronary heart disease. Platelets 2006;17:158-62.
47. Flammer JR, Dobrovolna J, Kennedy MA, et al. The type I interferon signaling pathway is a target for glucocorticoid inhibition. Mol Cell Biol 2010;30:4564-74.